SGTX — Sigilon Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $56.50m
- $17.21m
- $12.94m
- 30
- 21
- 77
- 38
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.64 | 14.2 | 13.4 | 9.6 | 12.9 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 27.7 | 58.3 | 66.4 | 85.2 | 56.6 |
Operating Profit | -23.1 | -44.1 | -53 | -75.6 | -43.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -22.8 | -43.9 | -54.6 | -77.3 | -43.6 |
Net Income After Taxes | -22.8 | -43.9 | -54.6 | -77.3 | -43.6 |
Net Income Before Extraordinary Items | |||||
Net Income | -22.8 | -43.9 | -54.6 | -77.3 | -43.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -25.8 | -43.9 | -54.6 | -77.3 | -43.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -11.1 | -18.9 | -22.4 | -31.5 | -17.5 |
Dividends per Share |